Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

(2018) Jingping Hu et al.   CANCER LETTERS

PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer

(2018) Daniela De Martino et al.   CANCER LETTERS

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties

(2017) Tony Siu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

(2017) Atli Thorarensen et al.   JOURNAL OF MEDICINAL CHEMISTRY

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules

(2017) Ana S. Newton et al.   ACS Medicinal Chemistry Letters

Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo

(2017) Guangyao Lv et al.   Acta Pharmaceutica Sinica B

Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer

(2016) Hassan Niknejad et al.   CELL AND TISSUE RESEARCH

Targeting cytokine signaling in autoimmunity: back to the future and beyond

(2016) Kiyoshi Hirahara et al.   CURRENT OPINION IN IMMUNOLOGY

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

(2015) Sara C. Meyer et al.   CANCER CELL

Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis

(2015) Greg L. Plosker   DRUGS

Therapy for myeloproliferative neoplasms: when, which agent, and how?

(2014) H. L. Geyer et al.   BLOOD

JAK/STAT pathway dysregulation in tumors: A Drosophila perspective

(2014) Marc Amoyel et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L

(2011) G Wernig et al.   LEUKEMIA

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

(2011) S Hart et al.   Blood Cancer Journal

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

(2010) P. Koppikar et al.   BLOOD

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

(2010) N. H. Thoennissen et al.   BLOOD

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders

(2009) Ana L. Basquiera et al.   Hematology

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

(2008) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY